These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 7655033)

  • 1. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.
    Kolb HJ; Schattenberg A; Goldman JM; Hertenstein B; Jacobsen N; Arcese W; Ljungman P; Ferrant A; Verdonck L; Niederwieser D; van Rhee F; Mittermueller J; de Witte T; Holler E; Ansari H;
    Blood; 1995 Sep; 86(5):2041-50. PubMed ID: 7655033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy with donor lymphocyte transfusions.
    Kolb HJ; Holler E
    Curr Opin Oncol; 1997 Mar; 9(2):139-45. PubMed ID: 9161791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
    Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
    Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
    Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
    Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
    Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: indications and dose escalation.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Ther Apher; 2001 Feb; 5(1):40-5. PubMed ID: 11258609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients.
    Mehta J; Powles R; Kulkarni S; Treleaven J; Singhal S
    Bone Marrow Transplant; 1997 Jul; 20(2):129-35. PubMed ID: 9244416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties.
    Kolb HJ
    Vox Sang; 1998; 74 Suppl 2():321-9. PubMed ID: 9704463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation.
    Porter DL; Roth MS; Lee SJ; McGarigle C; Ferrara JL; Antin JH
    Bone Marrow Transplant; 1996 Nov; 18(5):975-80. PubMed ID: 8932854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
    Porter DL; Roth MS; McGarigle C; Ferrara JL; Antin JH
    N Engl J Med; 1994 Jan; 330(2):100-6. PubMed ID: 8259165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.
    Mackinnon S; Papadopoulos EB; Carabasi MH; Reich L; Collins NH; Boulad F; Castro-Malaspina H; Childs BH; Gillio AP; Kernan NA
    Blood; 1995 Aug; 86(4):1261-8. PubMed ID: 7632930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic effect of donor leukocyte transfusion in relapsing marrow transplants in Japan].
    Shiobara S; Takahasi S; Yabe H; Maruta I; Kodera Y
    Rinsho Ketsueki; 1997 Nov; 38(11):1162-9. PubMed ID: 9423332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin.
    Finke J; Bertz H; Schmoor C; Veelken H; Behringer D; Wäsch R; Kunzmann R; Heidecker L; Lang H; Meyer-König U; Mertelsmann R
    Br J Haematol; 2000 Oct; 111(1):303-13. PubMed ID: 11091217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.